Stability-indicating study of the anti-Alzheimer's drug galantamine hydrobromide

L. de Azevedo Marques, I. Maada, F.J.J. De Kanter, H. Lingeman, H. Irth, W.M.A. Niessen, M.A. Giera

Research output: Contribution to JournalArticleAcademicpeer-review


Galantamine hydrobromide was subjected to different stress conditions (acidic, alkaline, thermal, photolytic and oxidative). Degradation was found to occur under acidic, photolytic and oxidative conditions, while the drug was stable under alkaline and elevated temperature conditions. A stability-indicating reversed-phase liquid chromatographic method was developed for the determination of the drug in the presence of its degradation products. The method was validated for linearity, precision, accuracy, specificity, selectivity and intermediate precision. Additionally, the degradation kinetics of the drug was assessed in relevant cases. The kinetics followed a first order behavior in the case of acidic and photolytic degradation, while a two-phase kinetics behavior was found for the oxidative degradation. The degradation products were characterized by mass spectrometry and nuclear magnetic resonance spectroscopy. Dehydration, epimerization and N-oxidation were the main processes observed during the degradation of galantamine. Moreover, if sufficient material could be isolated the inhibitory activity against the target enzyme acetylcholinesterase was also assessed. © 2011 Elsevier B.V.
Original languageEnglish
Pages (from-to)85-92
JournalJournal of Pharmaceutical and Biomedical Analysis
Issue number1
Publication statusPublished - 2011


Dive into the research topics of 'Stability-indicating study of the anti-Alzheimer's drug galantamine hydrobromide'. Together they form a unique fingerprint.

Cite this